dalteparin has been researched along with Crush Syndrome in 2 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Crush Syndrome: Severe systemic manifestation of trauma and ischemia involving soft tissues, principally skeletal muscle, due to prolonged severe crushing. It leads to increased permeability of the cell membrane and to the release of potassium, enzymes, and myoglobin from within cells. Ischemic renal dysfunction secondary to hypotension and diminished renal perfusion results in acute tubular necrosis and uremia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karahan, F | 1 |
| Ünal, S | 1 |
| Tezol, Ö | 1 |
| Sürmeli Döven, S | 1 |
| Durak, F | 1 |
| Alakaya, M | 1 |
| Mısırlıoğlu, M | 1 |
| Yeşil, E | 1 |
| Kıllı, İ | 1 |
| Kurt, H | 1 |
| Altunköprü, G | 1 |
| Takikawa, M | 1 |
| Nakamura, S | 1 |
| Ishihara, M | 2 |
| Takabayashi, Y | 1 |
| Fujita, M | 1 |
| Hattori, H | 1 |
| Kushibiki, T | 1 |
2 other studies available for dalteparin and Crush Syndrome
| Article | Year |
|---|---|
Thromboprophylaxis in pediatric patients with earthquake-related crush syndrome: a single centre experience.
Topics: Adolescent; Anticoagulants; Child; Crush Syndrome; Earthquakes; Enoxaparin; Female; Humans; Male; Th | 2023 |
Improved angiogenesis and healing in crush syndrome by fibroblast growth factor-2-containing low-molecular-weight heparin (Fragmin)/protamine nanoparticles.
Topics: Animals; Anticoagulants; Crush Syndrome; Dalteparin; Disease Models, Animal; Drug Evaluation, Precli | 2015 |